LONDON, ON, March 31, 2004 - KGK Synergize Inc. (“KGK” or the “Company”), a nutraceutical contract research and product development corporation located in London, ON, is pleased to announce the closing of an equity private placement of common shares. Janus Corporate Finance, a division of JR/Janus Merchant Brokers Ltd. (“JCF”) acted as the exclusive financial advisor to the Company. The size, terms and conditions of the transaction are not disclosed.
Ms. Najla Guthrie, co-founder and current President/CEO of KGK stated the following: “Throughout our history, our business model has been to reinvest the profits accumulated from the Contract Research division into developing new and innovative nutraceutical products in the areas of anti-cancer, cardiovascular, type II diabetes and anti-inflammatory. While this initiative has been successful to date, having licensed and supported the launch of SytrinolTM, a dietary supplement for cholesterol-lowering, we have many additional pipeline products in the clinical trial phase that have been delayed due to financing issues. This new capital will be used to support these products from the clinical trial phase through to commercialization.”
“SytrinolTM, which has been proven in three separate clinical trials to significantly lower LDL cholesterol and triglyceride levels in humans, is a perfect example of our business strategy to conduct rigourous scientific studies on our natural products before bringing them to market” Guthrie adds. SytrinolTM has been licensed by KGK to Chicago based SourceOne Global Partners for the dietary supplement market and has been launched in major US and European markets, carried by major industry players such as GNC and Jarrow Formulas.
The financing was arranged and structured by the Janus Corporate Finance division of JR/Janus Merchant Brokers Ltd., a Toronto based corporate finance and M&A advisory firm focused exclusively on mid-market transactions. “We rarely see management of this high caliber in emerging businesses; and when it is combined within an industry of such compelling fundamentals as are evident in nutraceuticals, the opportunity for investment success can be quickly and easily identified” said Michael J. Walker, President of JCF.
Other non-financial professionals assisting the Company in this transaction included Muirfield Advisors Inc. and McCarthy Tetrault, both of London, Ontario
About KGK Synergize Inc.:
KGK Synergize Inc. (London, ON) has been built on a solid scientific research foundation. Owned and operated by internationally renowned scientists in the field of nutraceuticals and functional foods, KGK brings a unique level of understanding, service and commitment to contract research that is unparalleled. Offering a wide range of services from pre-clinical studies to clinical trials, KGK provides full research services with tremendous time and financial efficiency, having in-house labs, a product development division, and a location that provides access to some of North America’s best facilities and staff. Visit their website at www.kgksynergize.com.
